Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Oligometastatic disease has been described as an intermediate clinical state between localized cancer and systemically metastasized disease. Recent clinical studies have shown prolonged survival when aggressive locoregional approaches are added to systemic therapies in patients with oligometastases. The aim of this review is to outline the newest options to treat oligometastatic colorectal cancer (CRC), also considering its molecular patterns. We present an overview of the available local treatment strategies, including surgical procedures, stereotactic body radiation therapy (SBRT), thermal ablation, as well as trans-arterial chemoembolization (TACE) and selective internal radiotherapy (SIRT). Moreover, since imaging methods provide crucial information for the early diagnosis and management of oligometastatic CRC, we discuss the role of modern radiologic techniques in selecting patients that are amenable to potentially curative locoregional treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2023.103990 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Effectiveness of Management Strategies for Stage IV Prostate Cancer: A Narrative Review.
Cureus
August 2025
Internal Medicine, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Awka, NGA.
Stage IV prostate cancer (PCa) refers to a disease that has metastasized beyond the prostate gland to distant sites, such as bones, visceral organs, or non-regional lymph nodes. While early attempts at curative therapy were occasionally made in oligometastatic cases, current guidelines uniformly recommend palliative-intent management once true metastatic spread is confirmed. Over the past decade, treatment paradigms have shifted from androgen deprivation therapy (ADT) monotherapy to earlier intensification with combination regimens including chemo-hormonal therapy and next-generation hormonal agents to improve survival and quality of life (QoL).
View Article and Find Full Text PDFMetastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial.
Lancet Oncol
September 2025
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background: Select patients with metastatic clear-cell renal-cell carcinoma can be treated without systemic therapy, yet few studies have explored this population. We investigated the efficacy of metastasis-directed therapy without systemic therapy in oligometastatic clear-cell renal-cell carincoma.
Methods: This investigator-initiated single-arm, phase 2 trial enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, histologically confirmed clear-cell renal-cell carcinoma, and one to five metastases.
CT-Based Radiomics Enhance Respiratory Function Analysis for Lung SBRT.
Bioengineering (Basel)
July 2025
Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Radiomics is the extraction of non-invasive and reproducible quantitative imaging features, which may yield mineable information for clinical practice implementation. Quantification of lung function through radiomics could play a role in the management of patients with pulmonary lesions. The aim of this study is to test the capability of radiomic features to predict pulmonary function parameters, focusing on the diffusing capacity of lungs to carbon monoxide (DL).
View Article and Find Full Text PDFMetabolic Imaging in Electrochemotherapy: Insights from FDG-PET Analysis in Metastatic Melanoma-A Pilot Study.
Cancers (Basel)
August 2025
Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, 80337 Munich, Germany.
: Electrochemotherapy (ECT) has emerged as a promising locoregional treatment modality for patients with cutaneous and subcutaneous melanoma metastases. While systemic therapies have improved overall disease control, effective local tumor management remains crucial, particularly in oligometastatic or symptomatic disease. This pilot study investigates the role of metabolic imaging with [F]FDG PET/CT to assess tumor metabolism in melanoma patients undergoing ECT, building on prior evidence that PET offers valuable functional information beyond anatomical changes detected by conventional imaging.
View Article and Find Full Text PDFMultinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.
Eur J Cancer
August 2025
Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.
Background: Distant progression is the predominant failure pattern after metastasis-directed stereotactic body radiotherapy (SBRT) for oligometastatic disease, but prognostic tools to guide post-progression management are lacking. We aimed to validate the prognostic value of distant metastasis velocity (DMV) for overall survival (OS) and widespread failure-free survival (WFFS) after distant progression.
Methods: Two independent international cohorts of patients with extracranial oligometastatic disease (≤5 lesions) who developed distant progression after SBRT were analyzed.